Publicly Funded Influenza Vaccines for Ontario this Season
Dear Health Care Professional:
This memorandum is to provide you with the current information regarding the 2021-22 Universal Influenza Immunization Program (UIIP).
While this memo focuses on influenza vaccine, it remains extremely important to reiterate with patients that they should complete their COVID-19 vaccination as soon as possible. As a reminder, individuals cannot receive a COVID-19 vaccine if they have received another vaccine within the past 14 days. This may impact the timing of flu vaccinations for your patients.
The support of primary care providers in the delivery of COVID-19 vaccinations is critical moving forward. See more information below on onboarding your practice to offer COVID-19 vaccinations.
It is recommended that all individuals ages 6 months or older who live, work or attend school in Ontario receive the influenza vaccine. *High-risk groups should be immunized first.
*Individuals at high risk of influenza-related complications or who are more likely to require hospitalization:
- All pregnant women
- People who are residents of nursing homes or other chronic care facilities
- People ≥ 65 years of age
- All children 6 to 59 months of age
- Indigenous peoples
- Adults or children 6 months of age and over with chronic health conditions as follows:
- Cardiac or pulmonary disorders
- Diabetes mellitus or other metabolic disease
- Cancer
- Conditions or medication which compromise the immune system (due to underlying disease, therapy or both
- Renal disease
- Anemia or hemoglobinopathy
- Neurologic or neurodevelopment conditions
- Morbid obesity (body mass index of ≥ 40)
- Children and adolescents (6 months to 18 years) undergoing treatment with acetylsalicylic acid for long periods
We highly recommend you review the implementation materials posted on The Ministry of Health and Long-Term Care (the Ministry) website, which includes program details, vaccine information, reporting requirements, fact sheets and other resources.
Influenza Virus Strains covered by the 2021/22 Influenza Vaccine:
- A/Victoria/2570/2019 (H1N1) pdm09-like virus
- A/Cambodia/e0826360/2020 (H3N2)-like virus
- A/Wisconsin/588/2019 (H1N1) pdm09-like virus
- B/Washington/02/2019-like strain
[B/Victoria lineage) – like virus] - B/Phuket/3073/2013-like strain
[B/Yamagata lineage) – like virus]
Products Available for 2021/22:
Vaccine Name | Manufacturer | Format | Age Indication | Dosage | Post-puncture Shelf life | Most Common Allergens |
FluLaval Tetra | GSK | MDV | ≥ 6 months | 0.5 ml/IM | Label Box/vial 28 days | Egg Protein Thimerosal |
Fluzone Quadrivalent | Sanofi | MDV/PFS | ≥ 6 months | 0.5 ml/IM | Label Box/vial MDV 28 days PFS N/A | Egg Protein Thimerosal (MDV) |
Afluria Tetra (Pharmacies) | Seqirus | MDV/PFS | ≥ 5 year | 0.5 ml/IM | Label Box/vial MDV 28 days PFS N/A | Egg Protein Neomycin Polymyxin B Thimerosal (MDV) |
Flucelvax Quadrivalent | Seqiurs | PFS | ≥ 2 years | 0.5 ml/IM | N/A | Does NOT contain Egg Protein or Thimerosal |
Fluzone High-Dose Quadrivalent | Sanofi | PFS | ≥ 65 years | 0.7 ml/IM | N/A | Egg Protein |
Fluad | Seqirus | PFS | ≥ 65 years | 0.5 ml/IM | N/A | Egg Protein Kanamycin Neomycin |
** Please refer to the Product Monograph for additional information
*According to the National Advisory Committee on Immunization (NACI), egg-allergic individuals may be vaccinated against influenza using the full dose of any appropriate product, including QIV, and high-dose QIV. Note: Flucelvax QIV does NOT contain egg protein.
Important Notes:
- Please ensure there is a 28 day interval since the clients last COVID vaccine
- Fluzone® Quadrivalent and Fluzone® High-Dose Quadrivalent are different products. Fluzone® High-Dose is only authorized for those 65 years of age and over. Please use caution when administering Fluzone® products to ensure that the right vaccine is being administered to the right person.
- Fluzone® High-Dose QIV and Fluad: Long Term Care & Ret Homes and QHC will be prioritized. Remaining supply will be equitably distributed to health care providers.